IBI-3001, potentially first-in-class B7-H3/EGFR bsADC with broad anticancer efficacy and excellent in vivo safety
April 9, 2024
At the AACR meeting, Innovent Biologics Inc. discussed the discovery and preclinical evaluation of a B7-H3/EGFR bispecific antibody-drug conjugate (bsADC).
